![Jeffrey Foy](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jeffrey Foy
Corporate Officer/Principal en PEPGEN INC. .
Cargos activos de Jeffrey Foy
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
PEPGEN INC. | Corporate Officer/Principal | - | - |
Oligonucleotide Therapeutics Society, Inc.
![]() Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Corporate Officer/Principal | - | - |
Historial de carrera de Jeffrey Foy
Antiguos cargos conocidos de Jeffrey Foy.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
DICERNA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
Formación de Jeffrey Foy.
Northeastern University | Graduate Degree |
University of Vermont | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 6 |
Operativa
Corporate Officer/Principal | 3 |
Graduate Degree | 1 |
Undergraduate Degree | 1 |
Sectorial
Health Technology | 3 |
Consumer Services | 3 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
PEPGEN INC. | Health Technology |
Empresas privadas | 2 |
---|---|
Dicerna Pharmaceuticals, Inc.
![]() Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
Oligonucleotide Therapeutics Society, Inc.
![]() Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Commercial Services |
- Bolsa de valores
- Insiders
- Jeffrey Foy
- Experiencia